Berberine sulfate (10, 30, or 50 mg/kg/day; gastrointestinal gavage; for 10 consecutive days) inhibits the growth of human colorectal adenocarcinoma in vivo. Berberine at doses of 30 and 50 mg/kg/day taken by gastrointestinal gavage shows inhibitory rates of 33.1% and 45.3% on the human colorectal adenocarcinoma xenograft growth in nude mice[1].
| Animal Model: | 5-week-old BALB/c nu/nu mice with human colorectal adenocarcinoma LoVo xenografts[1] |
| Dosage: | 10, 30, or 50 mg/kg/day |
| Administration: | Gastrointestinal gavage; for 10 consecutive days |
| Result: | Showed inhibitory rates of 33.1% and 45.3% at doses of 30 and 50 mg/kg/day.
|
